Selecta Biosciences (SELB) Stock Price, News & Analysis

Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.88 to $1.26
• 52-Week Range: N/A
• Volume: 2.77 million shs
• Average Volume: 979,585 shs
• Market Capitalization: $136.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Selecta Biosciences Stock Analysis - MarketRank™

Selecta Biosciences scored higher than 21% of companies evaluated by MarketBeat, and ranked 914th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Selecta Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Selecta Biosciences are expected to grow in the coming year, from ($0.33) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SELB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Selecta Biosciences does not currently pay a dividend.

Dividend Growth

Selecta Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.99

Short Interest

There is no current short interest data available for SELB.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for SELB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Selecta Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of Selecta Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

41.95% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SELB Stock Analysis - Frequently Asked Questions

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its quarterly earnings results on Thursday, August, 17th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The business earned $5.25 million during the quarter, compared to the consensus estimate of $9.90 million. Selecta Biosciences had a negative trailing twelve-month return on equity of 44.13% and a negative net margin of 72.04%.

When did Selecta Biosciences IPO?

Selecta Biosciences (SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 9/30/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SELB
• CUSIP: N/A
• CIK: 1453687
• Web: selectabio.com
• Phone: (617) 923-1400
• Fax: 617-924-3454
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $35.38 million
• Net Margins: -72.04%
• Pretax Margin: -73.23%
• Return on Equity: -44.13%
• Return on Assets: -22.00%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 4.18
• Quick Ratio: 4.18

Sales & Book Value

• Annual Sales: $110.78 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.91
• Book Value: $0.61 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 155,200,000
• Free Float: 106,780,000
• Market Cap: $136.76 million
• Optionable: Optionable
• Beta: 0.84